<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="600">
	<fontspec id="0" size="10" family="MinionPro" color="#231f20"/>
	<fontspec id="1" size="8" family="CAPNJB+MinionPro" color="#100e0c"/>
	<fontspec id="2" size="8" family="CAPNJB+MinionPro" color="#100e0c"/>
	<fontspec id="3" size="8" family="MinionPro" color="#231f20"/>
	<fontspec id="4" size="9" family="MinionPro" color="#231f20"/>
	<fontspec id="5" size="9" family="MinionMath" color="#231f20"/>
	<fontspec id="6" size="10" family="MinionPro" color="#000000"/>
	<fontspec id="7" size="10" family="MinionMath" color="#231f20"/>
	<fontspec id="8" size="10" family="MinionPro-It" color="#231f20"/>
	<fontspec id="9" size="12" family="Minion-Black" color="#231f20"/>
<text top="44" left="51" width="176" height="10" font="0">International Journal of Alzheimer‚Äôs Disease</text>
<text top="44" left="544" width="5" height="10" font="0">7</text>
<text top="76" left="79" width="40" height="8" font="1">P-Ser202Tau</text>
<text top="77" left="156" width="41" height="8" font="1">P-Thr231Tau</text>
<text top="76" left="239" width="35" height="8" font="1">Composite</text>
<text top="124" left="57" width="0" height="8" font="2">Un</text>
<text top="114" left="57" width="0" height="8" font="2">tr</text>
<text top="108" left="57" width="0" height="8" font="2">ea</text>
<text top="102" left="57" width="0" height="8" font="2">te</text>
<text top="96" left="57" width="0" height="8" font="2">d</text>
<text top="174" left="57" width="0" height="8" font="2">AC</text>
<text top="163" left="57" width="0" height="8" font="2">T</text>
<text top="252" left="57" width="0" height="8" font="2">A</text>
<text top="246" left="57" width="0" height="8" font="2">C</text>
<text top="241" left="57" width="0" height="8" font="2">T + JNK I</text>
<text top="209" left="57" width="0" height="8" font="2">n</text>
<text top="205" left="57" width="0" height="8" font="2">h</text>
<text top="298" left="57" width="0" height="8" font="2">JNK I</text>
<text top="279" left="57" width="0" height="8" font="2">n</text>
<text top="275" left="57" width="0" height="8" font="2">h</text>
<text top="324" left="167" width="9" height="8" font="3">(a)</text>
<text top="74" left="492" width="35" height="8" font="1">Composite</text>
<text top="123" left="310" width="0" height="8" font="2">Un</text>
<text top="113" left="310" width="0" height="8" font="2">tr</text>
<text top="108" left="310" width="0" height="8" font="2">ea</text>
<text top="101" left="310" width="0" height="8" font="2">te</text>
<text top="95" left="310" width="0" height="8" font="2">d</text>
<text top="174" left="310" width="0" height="8" font="2">AC</text>
<text top="163" left="310" width="0" height="8" font="2">T</text>
<text top="251" left="310" width="0" height="8" font="2">A</text>
<text top="246" left="310" width="0" height="8" font="2">C</text>
<text top="240" left="310" width="0" height="8" font="2">T + JNK I</text>
<text top="209" left="310" width="0" height="8" font="2">n</text>
<text top="204" left="310" width="0" height="8" font="2">h</text>
<text top="297" left="310" width="0" height="8" font="2">JNK I</text>
<text top="279" left="310" width="0" height="8" font="2">n</text>
<text top="274" left="310" width="0" height="8" font="2">h</text>
<text top="76" left="342" width="21" height="8" font="1">PHF-1</text>
<text top="75" left="409" width="41" height="8" font="1">P-Ser262Tau</text>
<text top="324" left="420" width="10" height="8" font="3">(b)</text>
<text top="343" left="51" width="498" height="9" font="4">Figure 4: ACT-mediated tau phosphorylation at p-Ser202, p-Thr231, PHF-1, and p-Ser262 in cortical neurons is inhibited by JNK inhibitor:</text>
<text top="353" left="51" width="355" height="9" font="4">mouse cortical neurons were cultured in 8-chamber slides and preincubated with JNK Inhibitor (10</text>
<text top="351" left="407" width="5" height="12" font="5">ùúá</text>
<text top="353" left="412" width="137" height="9" font="4">M, 1 hour). The cells were then treated</text>
<text top="364" left="51" width="498" height="9" font="4">with or without 1 mg/mL ACT for 8 hours and probed with (a) p-Ser202 tau monoclonal and p-Thr231 tau polyclonal, (b) PHF-1 tau</text>
<text top="374" left="51" width="498" height="9" font="4">monoclonal and P-Ser262 tau polyclonal antibodies. Anti-mouse Alexa fluor 488 (green) and anti-rabbit Alexa Flour 594 (red) were used</text>
<text top="384" left="51" width="498" height="9" font="4">as secondary antibodies, and Hoechst was used to visualize the nuclei. Staining was visualized under a Zeiss fluorescent microscope and</text>
<text top="395" left="51" width="158" height="9" font="4">analyzed using AxioVision Rel. 4.8 software.</text>
<text top="433" left="51" width="88" height="10" font="0">tau phosphorylation <a href="">(</a></text>
<text top="433" left="139" width="44" height="10" font="6"><a href="">Figure 3(b)</a></text>
<text top="433" left="183" width="107" height="10" font="0"><a href="">). </a>There was no significant</text>
<text top="445" left="51" width="240" height="10" font="0">change in P-JNK levels in the striatum or hippocampal region</text>
<text top="457" left="51" width="205" height="10" font="0">from ACT/mTau or ACT/mTau/hTau mice (Figures</text>
<text top="457" left="258" width="16" height="10" font="6"><a href="">3(a)</a></text>
<text top="457" left="276" width="15" height="10" font="0">and</text>
<text top="469" left="51" width="16" height="10" font="6"><a href="">3(c)</a></text>
<text top="469" left="66" width="225" height="10" font="0"><a href="">) </a>suggesting that the tau phosphorylation observed in</text>
<text top="480" left="51" width="240" height="10" font="0">these regions is brought about by kinases other than JNK.</text>
<text top="492" left="51" width="240" height="10" font="0">Our earlier studies in cultured neurons have shown that</text>
<text top="504" left="51" width="240" height="10" font="0">ACT-mediated tau hyperphosphorylation is associated with</text>
<text top="516" left="51" width="78" height="10" font="0">activation of GSK3</text>
<text top="513" left="129" width="11" height="13" font="7">ùõºùõΩ</text>
<text top="516" left="144" width="45" height="10" font="0">and ERK <a href="">[</a></text>
<text top="516" left="189" width="9" height="10" font="6"><a href="">23</a></text>
<text top="516" left="199" width="92" height="10" font="0"><a href="">]. </a>Here we found that</text>
<text top="527" left="51" width="240" height="10" font="0">JNK kinases are activated in response to ACT which in turn</text>
<text top="539" left="51" width="209" height="10" font="0">induces tau hyperphosphorylation. Although initial</text>
<text top="539" left="263" width="27" height="10" font="8"><i>in vivo</i></text>
<text top="551" left="51" width="194" height="10" font="0">analysis did not indicate any activation of GSK3</text>
<text top="549" left="244" width="11" height="13" font="7">ùõºùõΩ</text>
<text top="551" left="258" width="32" height="10" font="0">or ERK,</text>
<text top="563" left="51" width="209" height="10" font="0">further analysis is necessary to confirm these results.</text>
<text top="593" left="51" width="240" height="10" font="8"><i>3.4. Effect of JNK Inhibitor on ACT-Induced Tau Phosphoryla-</i></text>
<text top="604" left="51" width="131" height="10" font="8"><i>tion in Primary Cortical Neurons.</i></text>
<text top="604" left="186" width="104" height="10" font="0">To investigate our hypoth-</text>
<text top="616" left="51" width="240" height="10" font="0">esis that ACT enhances tau hyperphosphorylation through</text>
<text top="627" left="51" width="240" height="10" font="0">a JNK-dependent mechanism, we decided to investigate the</text>
<text top="639" left="51" width="240" height="10" font="0">effect of JNK inhibitor on tau phosphorylation in primary</text>
<text top="651" left="51" width="70" height="10" font="0">neurons cultured</text>
<text top="651" left="125" width="30" height="10" font="8"><i>in vitro</i></text>
<text top="651" left="159" width="131" height="10" font="0">and treated with ACT. Towards</text>
<text top="663" left="51" width="188" height="10" font="0">this, we pretreated cortical neurons with 10</text>
<text top="660" left="241" width="6" height="13" font="7">ùúá</text>
<text top="663" left="246" width="45" height="10" font="0">M of JNK</text>
<text top="674" left="51" width="240" height="10" font="0">inhibitor (SP600125) for 1 hour prior to addition of ACT</text>
<text top="686" left="51" width="240" height="10" font="0">and continued the incubation for 8 hours in the presence</text>
<text top="698" left="51" width="240" height="10" font="0">of ACT. The result showed an induction in phosphorylation</text>
<text top="710" left="51" width="240" height="10" font="0">of tau at different sites, which included PHF-1, p-Ser202, p-</text>
<text top="722" left="50" width="206" height="10" font="0">Thr231, and p-Ser262, upon ACT treatment (Figures</text>
<text top="722" left="258" width="16" height="10" font="6"><a href="">4(a)</a></text>
<text top="722" left="276" width="15" height="10" font="0">and</text>
<text top="733" left="51" width="17" height="10" font="6"><a href="">4(b)</a></text>
<text top="733" left="67" width="223" height="10" font="0"><a href="">). </a>Treatment with JNK inhibitor (SP600125) abolished</text>
<text top="433" left="309" width="240" height="10" font="0">the ACT-induced tau phosphorylation, indicating the regu-</text>
<text top="445" left="309" width="130" height="10" font="0">latory role of JNK in the process.</text>
<text top="472" left="309" width="67" height="11" font="9"><b>4. Discussion</b></text>
<text top="493" left="309" width="240" height="10" font="0">The involvement of ACT in AD is well documented, and</text>
<text top="504" left="309" width="50" height="10" font="0">its role in A</text>
<text top="502" left="359" width="6" height="13" font="7">ùõΩ</text>
<text top="504" left="368" width="181" height="10" font="0">oligomerization has been established. In the</text>
<text top="516" left="309" width="240" height="10" font="0">study presented here we sought to elucidate the mechanisms</text>
<text top="527" left="309" width="240" height="10" font="0">of ACT-induced tau phosphorylation, focusing on the role</text>
<text top="539" left="309" width="240" height="10" font="0">of JNK kinase, in order to increase our understanding of</text>
<text top="551" left="309" width="240" height="10" font="0">how this relevant kinase influences tau hyperphosphorylation</text>
<text top="563" left="309" width="240" height="10" font="0">and development of pathology in AD. Our studies illustrate</text>
<text top="574" left="309" width="185" height="10" font="0">that ACT by itself or in conjunction with IL-1</text>
<text top="572" left="494" width="6" height="13" font="7">ùõΩ</text>
<text top="574" left="503" width="46" height="10" font="0">induces tau</text>
<text top="586" left="309" width="240" height="10" font="0">phosphorylation and this is, at least in part, mediated by</text>
<text top="597" left="309" width="240" height="10" font="0">JNK activation. Mixed cultures of human glia from amyloid-</text>
<text top="608" left="309" width="240" height="10" font="0">prone cortical tissue show activation and expression of IL-</text>
<text top="620" left="309" width="240" height="10" font="0">1 and ACT, whereas mixed glial cultures from cerebellum</text>
<text top="631" left="309" width="240" height="10" font="0">failed to show such inflammatory response, suggesting that</text>
<text top="642" left="309" width="240" height="10" font="0">the regional specificities of amyloid deposition in AD may</text>
<text top="654" left="309" width="240" height="10" font="0">reflect on basic differences in inflammatory capacity between</text>
<text top="665" left="309" width="98" height="10" font="0">different brain regions <a href="">[</a></text>
<text top="665" left="406" width="10" height="10" font="6"><a href="">34</a></text>
<text top="665" left="416" width="133" height="10" font="0"><a href="">]</a>. For this reason, in the present</text>
<text top="676" left="309" width="240" height="10" font="0">study we decided to choose the brain regions that show</text>
<text top="688" left="309" width="240" height="10" font="0">pathological modifications in AD and examined them for</text>
<text top="699" left="309" width="59" height="10" font="0">changes in tau.</text>
<text top="711" left="324" width="225" height="10" font="0">The microglia surrounding the plaques in AD brain have</text>
<text top="722" left="309" width="217" height="10" font="0">been shown to express high levels of the cytokine IL-1</text>
<text top="720" left="525" width="6" height="13" font="7">ùõΩ</text>
<text top="722" left="534" width="15" height="10" font="0">and</text>
<text top="733" left="309" width="240" height="10" font="0">correlate with the extent of the pathology associated with</text>
</page>
</pdf2xml>
